Morgan Stanley Upgrades Merck Following mRNA Cancer Vaccine Breakthrough

Key Facts

1Morgan Stanley upgraded Merck (MRK) to Overweight with a price target of $179.00.

2Merck and Moderna announced successful Phase 3 results for their personalized mRNA cancer vaccine combined with Keytruda.

3Merck shares rose 12.61% to $152.22 following the announcement of the medical breakthrough.

In a move reflecting optimism toward innovative genomic therapies, Morgan Stanley upgraded Merck (MRK) to Overweight and set a new price target of $179.00. The upgrade follows the announcement by Merck and its partner Moderna of successful Phase 3 trial results for their personalized mRNA cancer vaccine combined with Keytruda. Clinical data indicated that the combination therapy significantly extended recurrence-free survival in patients with high-risk skin cancer.

Markets reacted strongly to the news, which marks the first successful Phase 3 result for an mRNA-based cancer therapy, driving Merck shares up by 12.61%. According to market data, the stock saw substantial momentum to reach $152.22, nearing its 52-week high. This performance underscores institutional confidence in the company's ability to strengthen its biopharmaceutical leadership through breakthrough medical innovations.

At the close of August 19, 2026, MRK was priced at $152.22 after reaching a session high of $153.47. Investors are now monitoring the sustainability of this price action given the lack of major upcoming economic catalysts in the immediate calendar, focusing instead on further regulatory updates regarding the new vaccine and its impact on the company's approximately $376 billion market capitalization.

Sources:

Financial Modeling Prep